118 related articles for article (PubMed ID: 7720173)
21. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
23. [The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors].
Liu J; Li M
Zhonghua Fu Chan Ke Za Zhi; 1995 May; 30(5):273-5. PubMed ID: 7648905
[TBL] [Abstract][Full Text] [Related]
24. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
26. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
29. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
Elferink F; van der Vijgh WJ; ten Bokkel Huinink WW; Vermorken JB; Klein I; Winograd B; Knobf MK; Simonetti G; Gall HE; McVie JG
Br J Cancer; 1987 Oct; 56(4):479-83. PubMed ID: 3689665
[TBL] [Abstract][Full Text] [Related]
31. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group.
DeGregorio MW; Lum BL; Holleran WM; Wilbur BJ; Sikic BI
Cancer Chemother Pharmacol; 1986; 18(3):235-8. PubMed ID: 3542268
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK
Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795
[TBL] [Abstract][Full Text] [Related]
33. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
Gietema JA; Veldhuis GJ; Guchelaar HJ; Willemse PH; Uges DR; Cats A; Boonstra H; van der Graaf WT; Sleijfer DT; de Vries EG
Br J Cancer; 1995 Jun; 71(6):1302-7. PubMed ID: 7779728
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Figg WD; Christian MC; Lush R; Link CJ; Davis P; Kohn E; Sarosy G; Rothenberg ML; Weiss RB; Ryan N; Jacobs J; Reed E
Biopharm Drug Dispos; 1997 May; 18(4):347-59. PubMed ID: 9158882
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
36. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
38. A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin.
Olver IN; Webster LK; Millward MJ; Stokes KH; Bishop JF
Cancer Chemother Pharmacol; 1995; 37(1-2):79-85. PubMed ID: 7497601
[TBL] [Abstract][Full Text] [Related]
39. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
40. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
